| |
|
|
|
IBC Life Sciences, Hotel @ MIT
February 9-10, 2004
At IBC’s Inaugural Ocular Angiogenesis conference, work will be described to show how such ocular diseases of neovascularization are observed and how therapies are being fashioned to attack these vascular disorders. We have learned much from the use of anti-angiogenic agents in the war of cancer. Now we are applying this therapeutic modality to the eye. Coverage highlights will include new modalities in the ocular aberrant neovascularization including cytokine antagonists, monoclonal antibodies, RNAi, soluble receptors, steroids, aminosterols, cocktail antagonists, small molecule drugs, oligonucleotide therapeutics and gene therapy.
|
|
|
|
|
|
|
|
Organized by:
|
|
IBC Life Sciences |
|
|
Invited Speakers:
|
|
Keynote Presentation: "Antiangiogenic Therapy for AMD: A National Priority"
Gerald J. Chander, M.D., Ph.D., Chief Scientific Officer, Foundation for Fighting Blindness
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
Phone (508) 616-5550 x1004
Fax (508) 616-5522
Email reg@ibcusa.com
Online www.LifeSciencesInfo.com/Angiogenesis
|
|
|
E-mail:
|
|
reg@ibcusa.com
|
|
|
|
|
|
|
|
|